| Name | Title | Contact Details |
|---|
Complete Senior Care is a Niagara Falls, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Brightline is the first full-family behavioral health solution built specifically to care for kids, teens, and parents across a range of common family challenges. Launched at a time when 1 in 5 children has a behavioral health condition and up to 80% don't get the care they need, with increasing need exacerbated by the Covid-19 pandemic, Brightline is here to help families across the country thrive. With multidisciplinary care teams, personalized family system care, evidence-based care delivery, and extraordinary technology, Brightline is able to support families with whatever challenges they’re facing and ultimately help them thrive long-term. With Brightline, families can access support for a range of needs with our digital platform that includes resources and education for parents, interactive treatment exercises, and more; 1:1 coaching to support kids, teens, and parents with skill-building and guidance for dealing with tough stuff; behavior therapy, medication support, and speech therapy for a range of behavioral and developmental health needs. All right from home, right when families need it most. Join us to bring extraordinary care to families across the country!
Foundations Associates is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Brentwood, TN. To find more information about Foundations Associates, please visit www.dualdiagnosis.org
AccessElite, on a mission to inspire leaders to build healthier, happier organizations through optimal wellbeing.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.